DHA Supplementation During Pregnancy Enhances Maternal Vagally Mediated Cardiac Autonomic Control in Humans

• Published in: The Journal of nutrition Vol. 152; no. 12; pp. 2708 - 2715
• Main Authors: Christifano, Danielle N, Chollet-Hinton, Lynn, Mathis, Nicole B, Gajewski, Byron J, Carlson, Susan E, Colombo, John, Gustafson, Kathleen M
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2022; American Institute of Nutrition; Oxford University Press
• Subjects: Autonomic nervous system; Blood pressure; Diet; Dietary intake; Dietary Supplements; docosahexaenoic acid; Docosahexaenoic Acids; Fatty acids; Fatty Acids, Omega-3; Female; Fetuses; Gestation; Heart rate; heart rate variability; Humans; Infant, Newborn; Longitudinal studies; Maternal & child health; Mothers; Nutrient Physiology, Metabolism, and Nutrient-Nutrient Interactions; Pregnancy; Premature babies; Premature Birth; Secondary analysis; Vagus nerve; Variance analysis; SD2; SD1; fatty acids; ANS; ICA; pregnancy; HR; DFA1; HRV; MCG; SPM; VLF; PNS; heart rate variability; docosahexaenoic acid; dietary supplements; SNS; LF; female; PANDA; bpm; HF; DC
• ISSN: 0022-3166; 1541-6100; 1541-6100
• DOI: 10.1093/jn/nxac178

DHA is an essential omega-3 (ω-3; n–3) fatty acid that has well-established benefits for the fetus. DHA also has the potential to influence the health of the mother, but this area is understudied. The objective of this secondary analysis was to determine if DHA was related to maternal heart rate (HR) and heart rate variability (HRV) metrics in a large cohort of pregnant women. In the parent trial (1R01HD086001) eligible participants (≥18 y old, English speaking, carrying a singleton pregnancy, 12–20 wk of gestation) were randomly assigned to consume 200 mg/d or 800 mg/d DHA for the duration of their pregnancy (n = 300). Weight, blood pressure, and magnetocardiograms (MCGs) were collected at 32 wk and 36 wk of gestation (n = 221). Measures of HR and HRV in time-, frequency-, and nonlinear-domains were determined from the isolated maternal MCG. Treatment group and timepoint were examined as predictors in association with HR and HRV metrics using random-intercept mixed-effects ANOVA unadjusted and adjusted models accounting for weight and dietary DHA intake. Women receiving the higher dose of DHA (800 mg/d) during pregnancy had lower HR, lower sympathetic index, higher vagally mediated HRV indices, and greater HRV complexity when compared with the women who received the lower dose (200 mg/d; all P < 0.05). All the dose relations remained significant even after controlling for the effect of time, maternal weight, and dietary DHA intake. DHA supplementation increases vagal tone in pregnant women. Longitudinal studies examining the potential link between DHA, enhanced vagal tone, and reported reduction in early preterm birth are warranted.